USA flag logo/image

An Official Website of the United States Government

CONTINUOUS CELL CULTURE FOR MONOCLONAL ANTIBODIES

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
460
Program Year/Program:
1984 / SBIR
Agency Tracking Number:
460
Solicitation Year:
N/A
Solicitation Topic Code:
N/A
Solicitation Number:
N/A
Small Business Information
Verax Corp
Etna Rd Hc 61 Box 6 Lebanon, NH 03766
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 2
Fiscal Year: 1984
Title: CONTINUOUS CELL CULTURE FOR MONOCLONAL ANTIBODIES
Agency: HHS
Contract: N/A
Award Amount: $434,930.00
 

Abstract:

THE OBJECTIVE FOR THIS PROJECT IS TO PROVE THE FEASIBILITY OF THE RESEARCH PLAN FOR A PHASE II PROGRAM TO DEMONSTRATE A LARGE COST REDUCTION FOR THE "IN VITRO" PRODUCTION OF MONOCLONAL ANTIBODIES. ACCORDING TO THE APPLICANT'S COMPANY'S SYSTEM, HYBRIDOMAS ARE IMMOBILIZED IN HYDROCOLLOIDGELS OR IN EXTENDED OPEN FOAM CARRIERS, BOTH IN THE FORM OF 0.1-0.5MM BEADS, AND CULTURED AS A THICK SLURRY IN A FLUIDIZED BIOREACTOR. THE COMPANY ALREADY HAS THIS TECHNOLOGY WELL DEVELOPED FOR YEAST AND BACTERIA CELLS. THETECHNICAL OBJECTIVE OF THE PHASE II RESEARCH PROGRAM IS TO OPTIMIZE HYBRIDOMA CULTURE WITH THIS SYSTEM FOR MINIMUM COSTOF PURIFIED ANTIBODY PRODUCT. THE COMMERCIAL OBJECTIVE IS TO ENABLE THE APPLICANT'S COMPANY TO MANUFACTURE FOR SALE LABORATORY AND PRODUCTION HYBRIDOMA-CULTURE SYSTEMS AND ALSOTO PRODUCE LOW-COST MONOCLONAL ANTIBODIES AS A CONTRACTOR MANUFACTURER. THE FIRST SCIENTIFIC OBJECTIVE IS TO UNDERSTAND THE BIOLOGICAL VARIABLES WHICH CONTROL ANTIBODY PRODUCTIVITY (MG/DAY/REACTOR VOLUME), YIELD (MG/1 OF MEDIA CONSUMED) AND ANTIBODY CONCENTRATION (MG/ML). A SECOND SCIENTIFIC OBJECTIVE IS TO ESTABLISH THE BASIS FOR OPTIMIZING SERUM-FREE NUTRIENT MEDIA AND IMMOBILIZATION MATERIALS AND METHODS TO MINIMIZE OVERALL COST OF CULTIVATION AND PURIFICATION. THE THIRD OBJECTIVE IS TO ESTABLISH MEANS TO MINIMIZE CELL GROWTH UNDER STEADY-STATE CONTINUOUS CULTURE WITHOUT INHIBITION OF IMMUNOGLOBULIN PRODUCTION, SO AS TO MAXIMIZE YIELD OF PRODUCT AND MINIMIZING THE RATE OF GENETIC ALTERATION IN THE CULTURE.

Principal Investigator:

Frederick Cahn
6036434400

Business Contact:

Small Business Information at Submission:

Verax Corp.
P.o. Box B-1170, Etna Road Hanover, NH 03755

EIN/Tax ID:
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No